Phytotherapy for functional dyspepsia: A review of the clinical evidence for the herbal preparation STW 5

Rösch, Wolfgang; Liebregts, Tobias; Gundermann, Karl‐Josef; Vinson, Bettina R.; Holtmann, Gerald

doi:10.1016/j.phymed.2006.03.022

Cited by 68 publications

(46 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…16,[20][21][22][23][24] The current study has demonstrated that Iberogast ® improved histological parameters including a reduced jejunal ODS score and improved villus and crypt structure in the jejunum during 5-FU induced mucositis; however, Iberogast ® did not improve sucrase activity as indicated by the SBT and the sucrase assay.…”

Section: Discussionmentioning

confidence: 49%

“…The current investigation treated rats with a 10% diluted solution of Iberogast ® ; however, in a clinical study using a dose 600 times the recommended daily dose of Iberogast ® , no toxic or negative side-effects were observed. 21 Therefore, for studies of mucositis, higher Iberogast ® doses may be required to exert maximal anti-oxidant effects.…”

Section: Discussionmentioning

confidence: 99%

“…[16][17][18][19] Iberogast ® is a herbal formula comprised of nine different extracts including Iberus amara (bitter candy tuft) (15%), Angelica archangelica (angelica root) (10%), Matricaria recutita (chamomile) (20%), Carum carvi (caraway) (10%), Silybum marianum (St. Mary's thistle) (10%), Melissa officinalis (lemon balm leaf ) (10%), Mentha piperita (peppermint leaf ) (5%), Chelidonium majus (celadine herb) (10%) and Glycyrrhiza glabra (liquorice root) (10%). 16 Iberogast ® has been clinically prescribed to treat gastrointestinal disorders such as functional dyspepsia (FD) for more than 40 years 16,[20][21][22][23][24] and has indicated promise in alleviating the symptoms of irritable bowel syndrome (IBS), markedly modulating gastrointestinal motor and sensory function. 21 Therefore, the aim of the current study was to investigate whether Iberogast ® could reduce small intestinal damage in a 5-FU model of mucositis in Dark Agouti rats.…”

Section: Introductionmentioning

confidence: 99%

“…16 Iberogast ® has been clinically prescribed to treat gastrointestinal disorders such as functional dyspepsia (FD) for more than 40 years 16,[20][21][22][23][24] and has indicated promise in alleviating the symptoms of irritable bowel syndrome (IBS), markedly modulating gastrointestinal motor and sensory function. 21 Therefore, the aim of the current study was to investigate whether Iberogast ® could reduce small intestinal damage in a 5-FU model of mucositis in Dark Agouti rats.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The herbal extract Iberogast® improves jejunal integrity in rats with 5-Fluorouracil (5-FU)-induced mucositis

Wright¹,

Yazbeck²,

Lymn³

et al. 2009

Cancer Biology & Therapy

View full text Add to dashboard Cite

There is an acute need for the development of effective therapies for mucositis, a debilitating side effect of cancer chemotherapy. Iberogast ® is a herbal extract reported to possess anti-inflammatory properties. We investigated Iberogast ® for its potential to reduce the severity of 5-Fluorouracil (FU)-induced mucositis in rats. Rats were allocated to three treatment groups (n = 8) and gavaged daily with a 10% solution of Iberogast ® or water from day 0 to day 8. Rats were injected intraperitoneally with 5-FU (150 mg/kg) or saline on day 6, and killed after 72 h. In vivo and in vitro sucrase activity was assessed by 13 C-sucrose breath test (SBT) and sucrase assay respectively. Intestinal disease severity was determined by histological assessment of villus height and crypt depth. Significant increases in villus height (277 ± 9 μm) and crypt depth (67 ± 3 μm) were observed in 5-FU + Iberogast ® -treated rats compared with 5-FU + Water (224 ± 13 μm and 48 ± 2 μm respectively; p < 0.05). Sucrase activity was significantly reduced in all 5-FU groups compared to control. Significant reductions in SBT and sucrase activity were observed in all 5-FU groups compared with Saline + Water controls (p < 0.05). We conclude that although Iberogast ® partially improved the histopathological features of 5-FU induced mucositis, it conferred no significant protection as indicated by the assessed endpoints.

show abstract

Section: Discussionmentioning

confidence: 49%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The herbal extract Iberogast® improves jejunal integrity in rats with 5-Fluorouracil (5-FU)-induced mucositis

Wright¹,

Yazbeck²,

Lymn³

et al. 2009

Cancer Biology & Therapy

View full text Add to dashboard Cite

show abstract

“…Herbal preparations containing peppermint have been successful in the treatment of functional dyspepsia [96], although whether this is a sensory or motor effect and whether it is mediated via TRPM8 remain to be seen. Several clinical trials have been conducted with selective TRP antagonists for pain [97], such as the TRPV1 antagonist, AMG-517, which was discontinued due to hyperthermia after systemic administration.…”

Section: Therapeutic Opportunitiesmentioning

confidence: 99%

TRP Channels in Visceral Pain

Blackshaw¹,

Brierley²,

Harrington³

et al. 2013

TOPAINJ

View full text Add to dashboard Cite

Visceral pain is both different and similar to somatic pain - different in being poorly localized and usually referred elsewhere to the body wall, but similar in many of the molecular mechanisms it employs (like TRP channels) and the specialization of afferent endings to detect painful stimuli. TRPV1 is sensitive to low pH. pH is lowest in gastric juice, which may cause severe pain when exposed to the oesophageal mucosa, and probably works via TRPV1. TRPV1 is found in afferent fibres throughout the viscera, and the TRPV1 agonist capsaicin can recapitulate symptoms experienced in disease. TRPV1 is also involved in normal mechanosensory function in the gut. Roles for TRPV4 and TRPA1 have also been described in visceral afferents, and TRPV4 is highly enriched in them, where it plays a major role in both mechanonociception and chemonociception. It may provide a visceral-specific nociceptor target for drug development. TRPA1 is also involved in mechano-and chemosensory function, but not as selectively as TRPV4. TRPA1 is colocalized with TRPV1 in visceral afferents, where they influence each other's function. Another modulator of TRPV1 is the cool/mint receptor TRPM8, which, when activated can abrogate responses mediated via TRPV1, suggesting that TRPM8 agonists may provide analgesia via this pathway. In all, the viscera are rich in TRP channel targets on nociceptive neurones which we hope will provide opportunities for therapeutic analgesia.

show abstract